UK tech assessment
This article was originally published in The Gray Sheet
Stakeholders affected by the impending seventh wave of the National Institute for Clinical Excellence work program should complete the NICE 1registration form before timetables are announced at the end of June. The UK Department of Health and the Welsh Assembly Government identify stakeholders as: patient organizations; health professional groups; and manufacturers with technologies in the clinical area covered by the scope of the program guidelines. Primary care organizations and acute trusts will be selected at random and invited to participate. NICE says that the assessment will include drug-eluting stent performance for atherosclerotic events and the prevention of restenosis (2"The Gray Sheet" May 27, 2002, p. 10)...
You may also be interested in...
The UK National Institute for Clinical Excellence will release its timetable for a drug-eluting stent technology assessment by the end of June, according to Chief Executive Andrew Dillon
SK set for Korean trial with vaccine, as Biological E begins human trials of Baylor vaccine. Meanwhile, DongWha gets a Phase II nod for potential drug, and Celltrion progesses with Phase II regdanvimab trial.
UK start up Iceni Diagnostics has secured funding to develop its test for the live, intact SARS-CoV-2 virus and the UK government is evaluating a lateral flow device based on the technology for testing saliva samples as part of efforts to step up rapid testing in the country.